Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Title
Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Identifier
/unibl/sci/idNaucniRad:36016
Type
See all items with this valueAcademic Article
Date
Bibliographic Citation
LJ. Božić, Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, STED Journal, Sep, 2016
Is Part Of
See all items with this valueSTED Journal
See all items with this value2637-2150
list of authors
Position: 138119 (14 views)